China’s NMPA clears CSPC Pharmaceutical’s SYS-6023 to enter clinic for solid tumors

March 21, 2024

CSPC Pharmaceutical Group Ltd. has obtained clearance by China’s National Medical Products Administration (NMPA) to conduct clinical trials in China with SYS-6023 for advanced solid tumors.

BioWorld Science Regulatory Cancer Antibody-drug conjugate Immuno-oncology NMPA

Today's news in brief

BioWorld

BioWorld briefs for March 20, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 20, 2025

Lost in trans-lation? Trump’s mouse charge doesn’t click

BioWorld

U.S. President Donald Trump touched off a not-uncommon flurry of puzzlement and outrage when, during his speech to Congress on March 4, he referred to an example...

Clinical trial fraud ends with guilty pleas

BioWorld

In another real-life episode of “sponsor beware,” the owners of a clinical research facility pleaded guilty March 10 in U.S. district court to fraud charges...

At CROI, HIV cure trials raise hopes for broader applicability

BioWorld

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...